Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
Status:
Completed
Trial end date:
2016-12-21
Target enrollment:
Participant gender:
Summary
The primary objective(s) of the study are to assess the BG00012 (dimethyl fumarate) treatment
effect on cognition over 2 year period in RRMS patients. The secondary objectives of this
study are to further assess BG00012 treatment effect on cognition, predictors of cognitive
impairment, clinical efficacy, and patient reported outcomes (PRO): depression, fatigue,
quality of life, and work and social life activity.